论文部分内容阅读
Objective: To evaluate the clinical activity of angiogenesis inhibitor Endostar (rh-endostatin) in combination with continued EGFR-TKIs (including erlotinib, gefitinib and IcotinibO) for advanced NSCLC patients who have developed acquired resistance to prior EGFR-TKIs treatment.